About

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Zantrene

Zantrene® is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be an important to the progression of a wide range of cancers. Race Oncology is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers.

The Company has compelling clinical data for the use of Zantrene® as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene®.

Review our plans under the Three Pillar strategy via our 2020 strategic update which was released to the ASX on 30 November 2020.

Race is led by a seasoned team and Board, supported by a network of key opinion leaders and collaborators. See our leadership team here.


History

2021

Zantrene in the clinic for AML and preclinical programs launched for a range of FTO driven cancers

2020

The ‘new’ Race launched with the announcement of the Three Pillar Strategy

2019

5-Path Strategy announced advancing Zantrene® in AML, Breast and Ovarian Cancers,

2016

Race Oncology lists on the ASX (RAC) with the mission to rescue Zantrene® and return it to the clinic.

2011-2015

Zantrene® rediscovered, new patents filed and orphan drug designation obtained.

1990s

Zantrene® was approved for marketing in France for the treatment of AML. Further Zantrene development stopped after issues with the Phase III Breast cancer trial design.

1980s

More than 40 published clinical trials run assess Zantrene’s efficacy and safety in a wide range of cancers including leukemias, breast and ovarian. The studies covered more than 2,000 treated patients and revealed that Zantrene® was shown to possess low cardiotoxicity potential and useful therapeutic efficacy in several cancers, notably AML, Breast and Ovarian.

1970s

Zantrene® discovered in the pharmaceutical company Lederle Laboratories.